Background: CDK9 inhibitors are antitumorigenic against solid tumors, including esophageal adenocarcinoma (EAC). However, efficacy of a CDK9 inhibitor combined with 5-fluorouracil (5-FU) and target proteins that are targeted by these agents in EAC are unknown.
Introduction
Preoperative chemotherapy or chemoradiation followed by surgery have improved survival outcomes and the likelihood of margin-negative esophagogastrectomy in patients with locoregional esophageal adenocarcinoma (EAC). 1 However, these patients' 5-year survival rates remain low. 2, 3 Biomarkerdriven targeted therapies have had limited success in EAC patients, primarily in less than 20% of those with stage IV human epidermal growth factor receptor 2 (Her2-neu)-overexpressing disease who receive trastuzumab. [4] [5] [6] To date, no targeted agent has demonstrated benefit as an adjunct to 5-fluorouracil-based chemotherapy or chemoradiation in patients with locally advanced EAC.
EAC, but not normal esophageal squamous epithelium or Barrett esophagus, overexpresses cyclin-dependent kinase 9 (CDK9), an evolutionarily conserved ubiquitous serine threonine kinase. 7 CDK9 is a transcriptional CDK and an essential component of positive transcription elongation factor b (p-TEFb). p-TEFb, which phosphorylates the carboxy terminal of RNA polymerase II, prolongs the transcription of proteins with short half-lives, such as myeloid cell leukemia-1 (MCL-1). MCL-1 and other CDK9-regulated proteins play important roles in several cellular processes critical to oncogenesis. Some of these processes, such as apoptosis, are enhanced by CDK9 inhibition and chemotherapy. CDK9 inhibitors and chemotherapeutic agents, owing to their common cellular mechanism, very likely have synergy against tumors. [8] [9] [10] In phase I/II trials, CDK9 inhibitors elicited limited treatment responses and had high toxicity in patients with solid tumors. [11] [12] [13] [14] [15] [16] These drugs' low efficacy is partly due to their lack of specificity against CDK9. Therefore, demonstration of target specificity against CDK 9 is important in improving efficacy of the CDK9 inhibitors. In one recent study, we demonstrated the efficacy of two CDK inhibitors with predominant CDK9 inhibitory effects in in vitro and xenograft models of EAC; we also demonstrated that CDK9 downregulation by shRNA (shCDK9) and treatment with a CDK inhibitor reduces the phosphorylation of RNA polymerase II at serine 2, a CDK9-specific function, and downregulates common CDK9 targets such as MCL-1 and c-Myc in EAC. 7 These findings indicate that CDK9 inhibitors have on target effects against CDK9 in EAC.
One novel first-in-class CDK9-specific inhibitor, BAY1143572 (Atuveciclib), potently inhibits CDK9 (p-TEFb) activity; its effect against CDK9 is more than 50-fold greater than that against other CDKs. One recent study showed that BAY1143572 inhibits pSer2 and pSer7 RNA Pol II, as well as MYC and MCL-1, and induces apoptosis in adult T-cell leukemia and lymphoma. 17, 18 In preclinical models of solid tumors, BAY1143572 at nanomolar doses had antitumor activity without any off-target effects, indicating its high specificity for CDK9. 19 Recently, we have demonstrated radiation-sensitizing effects of BAY1143572 in preclinical models of EAC (manuscript under review). However, whether BAY1143572 or any other CDK9 inhibitor have a role as an adjuvant to chemotherapy for EAC is not known.
In this study, we assessed the synergy between BAY1143572 and 5-fluorouracil in suppressing tumor growth and downregulating MCL-1 in in vitro and xenograft models of EAC. In vivo experiments were performed with murine xenografts because of ability to test the efficacy and toxicity of a drug against intact tumor and normal tissue in these models. Experiments with xenograft models generate robust preclinical data, an essential step before proceeding to a human clinical trial. Furthermore, we also studied the prognostic relevance of tumor cell MCL-1 expression in patients with locoregional EAC treated with neoadjuvant chemoradiation (including 5-fluorouracil) and esophagogastrectomy. By these experiments, we have tested a hypothesis that BAY1143572 and 5-fluorouracil have synergistic antitumorigenic properties against EAC and MCL-1 is a shared target of these two agents.
Material and methods
The study was approved by MD Anderson's Institutional Review Board (PA15-0887 and LAB04-0979, PI: DMM). The requirement for informed consent was waived because all samples were from residual tissue in blocks generated for standard-of-care pathology processing and no additional sampling from patients was required. 
EAC xenograft studies
The animals were provided by Jackson Laboratories (MD, USA) or Experimental Radiation Oncology, MD Anderson Cancer Center. All xenografts experiments were performed with 4-to 6-week-old female athymic nu/ nu mice, whose mean weight was 20 g (range, 17-22 g). All mice were treatment naïve and did not undergo any genetic manipulation. We chose athymic nu/nu mice because these immunodeficient rodents cannot reject implanted tumor and the rate of tumor growth in these models is predictable. Female mice were used because of timely availability of the female athymic nu/nu mice as compared with male mice. All laboratory animals were kept in modified barrier housing. All animals had social housing and environmental enrichment in accordance with the current edition of the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act. BAY1143572 (7.5 mg/ml) and 5-fluorouracil (10 mg/ml) were dissolved in DMSO (vehicle) to generate injectable formulations. To identify the effective dose of BAY1143572, we subcutaneously injected 4.5 × 10 6 FLO-1 cells into the right flanks of the mice. Once the tumors reached 5 mm in diameter, the mice were randomly divided into three treatment cohorts of seven mice each: (1) a control cohort treated with vehicle only; (2) a cohort treated with 12.5 mg/kg BAY1143572; and (3) a cohort treated with 15 mg/kg BAY1143572. Vehicle alone or BAY1143572 were given daily (in the morning) by intraperitoneal injection for 10 days under isoflurane vaporizer anesthesia. Isoflurane vaporizers are traditional anesthetic systems that allow proper, safe, and effective delivery of inhalant anesthetic agent to rodents.
To assess the synergistic effect of BAY1143572 and 5-fluorouracil in inhibiting the growth of EAC For all xenograft experiments, BAY1143572 was given daily (in the morning) for 10 days and 5-fluorouracil (in the morning) was given every 3 days for 2 weeks; both agents were given by intraperitoneal injection. The number of mice for the cohorts was decided based on our prior studies. treated with vehicle only. In addition, the mean xenograft volume of the cohort treated with BAY1143572 plus 5-fluorouracil was 55% smaller than that of the cohort treated with 5-fluorouracil alone and 33% smaller than that of the cohort treated with BAY1143572 alone ( Figure 2C ).
Results

BAY1143572 is cytotoxic to EAC in vitro and
Xenograft-bearing mice treated with 15 mg/kg BAY114372 plus 5-fluorouracil had significant weight loss during the treatment period but were able to gain weight after the treatment was stopped. No other signs of toxicity were observed in any treatment group. 
MCL-1 upregulation decreases BAY1143572's proapoptotic effects against EAC in vitro
MCL-1 was robustly upregulated in 3 cell lines ( Figure 5C ). In FLO-1 cells, MCL-1 upregulation reduced apoptosis by 21% after treatment with 0.5 µM BAY1143572, 18% after treatment with 5 µM 5-fluorouracil, and 31% after treatment with BAY1143572 plus 5-fluorouracil as compared with the matching control (p < 0.01). In SKGT4 cells, MCL-1 upregulation reduced apoptosis by 5% after treatment with 0.5 µM BAY1143572, 10% after treatment with 5-fluorouracil, and 8% after treatment with BAY1143572 plus 5-fluorouracil as compared with the matching control (p < 0.01; Figure 5D ).
High MCL-1 expression in pretreatment tumor cells predicts shorter overall survival in patients with locoregional EAC
The median H-score of MCL-1 expression in tumor cells in pretreatment samples was 40 Figure 6A ) and those whose tumors had high MCL-1 expression (H ⩾ 40; Figure 6B ), as shown in Supplementary Table 2 .
Kaplan-Meier analysis showed that patients with high MCL-1 expression had significantly worse and overall and recurrence (or time to death) survival, than patients with low MCL-1 expression did ( Figure 6C and D) . The median overall survival duration of patients with tumors with low MCL-1 expression (65 months) was significantly longer than that of patients with tumors with high MCL-1 expression (30 months), p = 0.0.012). In the Cox regression univariate analysis, higher pathologic nodal stage, receipt of therapy for recurrence, and high tumor cell MCL-1 expression were associated with shorter overall survival. In the multivariate analysis, high tumor cell MCL-1 expression and receipt of therapy for recurrence were associated with shorter overall survival, whereas pathologic nodal stage demonstrated a trend towards an association with shorter overall survival ( Table 1 ). The median recurrencefree (or time to death) survival duration of patients with tumors with low MCL-1 expression (60 months) was significantly longer than that of patients with tumors with high MCL-1 expression (18 months, p = 0.008). In the Cox regression univariate and multivariate analyses, higher pathologic nodal stage and high tumor cell MCL-1 expression were associated with shorter recurrence-free (or time to death) survival (Table 2) .
Discussion
The results of our in vitro and xenograft experiments demonstrate that the inhibition of CDK9/ p-TEFb by BAY1143572 alone or in combination with 5-fluorouracil is effective against EAC. In this study, BAY1143572's dose-dependent effects on cell proliferation and its narrow range of IC 50 in six EAC cell lines suggest that CDK9 inhibitors have efficacy against EAC.
The findings of the present study and a previous study 7 demonstrate that three CDK inhibitors with predominant CDK9 inhibitory effects, BAY1143572, flavopiridol, and CAN508, have similar antitumorigenic effects against EAC. These drugs also downregulate the phosphorylation of RNA Pol II and transcriptionally downregulate MCL-1 by inhibiting HIF1-α binding to the MCL-1 promoter in EAC. These results indicate that BAY1143572 has on-target effects against CDK9 in EAC. BAY1143572's higher specificity against CDK9/p-TEFb and strong efficacy in vitro and in murine xenografts of EAC support a study investigating the role of BAY1143572 as an adjunct to chemotherapy or radiotherapy in EAC.
5-fluorouracil is one of the most widely used agents in bimodality and trimodality neoadjuvant therapy as well postoperative chemotherapy in patients with esophageal or gastroesophageal junction adenocarcinoma. 1, [26] [27] [28] However, few studies have assessed the role of targeted agents in combination with 5-fluorouracil-based chemotherapy or chemoradiotherapy in EAC. Most of these studies are limited to targeted agents whose efficacy has already been established in other solid tumors. [29] [30] [31] [32] [33] [34] Ours is the first study to demonstrate synergy between a CDK9 inhibitor and 5-fluorouracil in vitro and in inhibiting the growth of murine xenografts of EAC. The BAY1143572 dose required to achieve synergy varied across cell lines; a dose lower than the IC 50 was required for OE33 and FLO-1 cells, whereas a dose close to the IC 50 was required for SKGT4 cells, indicating a heterogeneity of response to BAY1143572 in combination with 5-fluorouracil. Unlike synergy in proliferation in all three EAC cell lines, BAY1143572 significantly enhanced the effects of 5-fluorouracilinduced apoptosis in FLO1 and SKGT4 cells but not in OE33 cells. These findings suggest heterogeneity in the synergistic effects of these agents across different EAC cells. It is likely that effects of BAY1143572 with and without 5-fluorouracil in OE33 and ESO26 are by different mechanism such as cell cycle arrest in G1 or G2-M phase.
In xenograft experiments, synergy between 15 mg/ kg BAY1143572 and 5-fluorouracil was evident in One limitation of the present study was the lack of validation of the synergistic effects of BAY1143572 and 5-fluorouracil on MCL-1 in xenografts. MCL-1, a protein with a short half-life, is regulated by multiple mechanisms. At the end of the experiments, xenografts were unlikely to have reduced MCL-1 levels owing to the transient and reversible effects of CDK9 inhibition on MCL-1 and the normalization of MCL-1 levels by other compensatory mechanisms. [35] [36] [37] MCL-1 levels in xenografts should be measured immediately after CDK9 inhibitor treatment to demonstrate the effects of CDK9 inhibitors on MCL-1 in xenografts.
MCL-1 is a ubiquitous protein whose expression pattern in EAC is not known. For this reason and to obtain an MCL-1 H-score cut-off that can be used to classify patients as those with good versus those with poor response to neoadjuvant chemoradiation, we used the H-score method and median level of the H-score as the cut-off. We found that MCL-1 expression in patients' tumor cells was correlated with survival outcomes, further supporting the substantial role MCL-1 has in EAC biology and behavior. Our results showing that MCL-1 expression is at least as significant as established prognostic factors such as nodal stage. This finding indicates that further studies investigating MCL-1 as predictor of neoadjuvant therapy response in patients with localized EAC are warranted.
Our RPPA data showing the upregulation of ATMpS1981 38 and FOX-M1 39, 40 indicate that the DNA damage repair mechanism is a likely mechanism of synergy between BAY1143572 and 5-fluorouracil. The downregulation of LGRP6pS1490 and MNK1 suggest a synergistic role of BAY1143572 and 5-fluorouracil in the Wnt pathway and/or MAP kinase pathway 41 in EAC.
In conclusion, the present study provides ample preclinical data supporting a clinical trial of BAY1143572 alone or in combination with 5-fluorouracil in patients with EAC, using MCL-1 as a potential predictor of response to these therapies. 
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